Results 191 to 200 of about 1,204,981 (346)

Concomitants, Categories, and Constraints [PDF]

The Behavior Analyst, 1993
openaire   +2 more sources

Circulating tumor DNA monitoring and blood tumor mutational burden in patients with metastatic solid tumors treated with atezolizumab

Molecular Oncology, EarlyView.
In patients treated with atezolizumab as a part of the MyPathway (NCT02091141) trial, pre‐treatment ctDNA tumor fraction at high levels was associated with poor outcomes (radiographic response, progression‐free survival, and overall survival) but better sensitivity for blood tumor mutational burden (bTMB).
Charles Swanton, Russell W. Madison, Candice Francheska B. Tambaoan, Funda Meric‐Bernstam, Christopher J. Sweeney, Razelle Kurzrock, Howard A. Burris III, David R. Spigel, Hanna Tukachinsky, Jason Hughes, Julia Malato, Bongin Yoo, Tania Szado, Cheryl Schwab, Lincoln W. Pasquina, Amaya Gasco, Katja Schulze, Claire F. Friedman   +17 more
wiley   +1 more source

Effect of Cartilage Injuries on Medial Patellofemoral Ligament Reconstruction Outcomes at Midterm Follow-up. [PDF]

Orthop J Sports Med
Davies MR, Propp BE, Marmor WA, Papapill NK, Wimberly AC, Nguyen JT, Shubin Stein BE, Dennis ER.   +7 more
europepmc   +1 more source

Concomitant Lymphoma and Carcinoma

Annals of Saudi Medicine, 1991
Abdel Rahman El-Shiekh Mohammed, Kamla H. Sidky, Muffak Jawdat, Yasawy Mi, Mohamed A. Al-Karawi   +4 more
openaire   +3 more sources

Concomitant aneurysms of the thoracic and abdominal aorta

, 1968
P Welsh, Ladislao Iraola
openalex   +1 more source

Dose‐dependent induction of epithelial‐mesenchymal transition in 3D melanoma models by non‐thermal plasma treatment

Molecular Oncology, EarlyView.
Non‐thermal plasma treatment of melanoma cells induced epithelial‐mesenchymal transition (EMT) in a dose‐dependent fashion. This report highlights the critical need to further investigate potential adverse effects of non‐thermal plasma for cancer therapy and to optimize treatment parameters for clinical translation. Despite the promising results of non‐
Eline Biscop, Edgar Cardenas De La Hoz, Hanne Verswyvel, Joey De Backer, Ho Wa Lau, Angela Privat‐Maldonado, Wim Vanden Berghe, Steve Vanlanduit, Evelien Smits, Annemie Bogaerts, Abraham Lin   +10 more
wiley   +1 more source

Loneliness and analgesic overuse among low-dose estrogen-progestin users in Japan. [PDF]

BMC Womens Health
Fujimoto T, Iwata H, Kobayashi N, Kondo S, Yamaura K.   +4 more
europepmc   +1 more source

Induction TPF followed by concomitant treatment versus concomitant treatment alone in locally advanced head and neck cancer. A phase II–III trial

Annals of Oncology, 2017
M. Ghi, A. Paccagnella, D. Ferrari, P. Foa, D. Alterio, C. Codecà, F. Nolè, E. Verri, R. Orecchia, F. Morelli, S. Parisi, C. Mastromauro, C. Mione, C. Rossetto, M. Polsinelli, H. Koussis, L. Loreggian, A. Bonetti, F. Campostrini, G. Azzarello, C. D'Ambrosio, F. Bertoni, C. Casanova, E. Emiliani, M. Guaraldi, F. Bunkheila, P. Bidoli, R. Niespolo, A. Gava, E. Massa, A. Frattegiani, F. Valduga, G. Pieri, T. Cipani, D. Da Corte, F. Chiappa, E. Rulli   +36 more
semanticscholar   +1 more source

CONCOMITANT EFFECTS OF INSULIN ON SURFACE MEMBRANE CONFORMATION AND POLYSOME PROFILES OF SERUM-STARVED BALB/C 3T3 FIBROBLASTS [PDF]

, 1974
R. Blair Evans, Vera B. Morhenn, Albert L. Jones, Gordon M. Tomkins   +3 more
openalex   +1 more source

Molecular imaging predicts trastuzumab‐deruxtecan (T‐DXd) response in head and neck cancer xenograft models

Molecular Oncology, EarlyView.
Trastuzumab‐deruxtecan, a HER2‐targeting antibody‐drug conjugate, shows promising antitumor activity in head and neck squamous cell carcinoma with low HER2 expression. In vitro and in vivo studies demonstrated dose‐dependent cell death and tumor growth reduction in low HER2‐expressing cell lines, which correlated with drug accumulation measured using a
Abdullah Bin Naveed, Lucas Mani, Muhammad Bilal Mirza, Ashtyn McAdoo, Takahito Kondo, Hidenori Tanaka, Nicole Meeks, Eben Rosenthal, Marisa Hom   +8 more
wiley   +1 more source